Big Pharma’s bottom line is leaving the world vulnerable to pandemics

  • “The possibility for blockbuster sales motivates large drugmakers; little else moves the needle. The revenue potential for many infectious disease drugs is likely to remain limited, so other serious incentives are required,” Bloomberg Opinion’s Max Ni…
    Read More

Comments

mood_bad
  • No comments yet.
  • Add a comment